The antimicrobial potential of cannabidiol

Area of Science:

• Pharmacology
• Microbiology
• Natural Products

Background:

• Antimicrobial resistance (AMR) poses a significant threat to global health, necessitating novel therapeutic strategies.
• The pipeline for new antibiotics, especially against Gram-negative bacteria, is critically limited.

Purpose of the Study:

• To evaluate the antimicrobial activity of cannabidiol (CBD), a non-psychoactive cannabis component.
• To investigate CBD's mechanism of action, resistance potential, and in vivo efficacy.
• To explore CBD analogs as a potential new class of antibiotics.

Main Methods:

• Testing CBD against a range of Gram-positive and Gram-negative bacterial pathogens, including resistant strains.
• Assessing CBD's efficacy against bacterial biofilms and its propensity to induce resistance.
• Conducting in vivo topical efficacy studies and mode-of-action investigations.
• Performing structure-activity relationship studies on CBD analogs.

Main Results:

• CBD demonstrated significant antimicrobial activity against Gram-positive bacteria (e.g., Staphylococcus aureus, Streptococcus pneumoniae, Clostridioides difficile) and biofilms.
• CBD exhibited low propensity for inducing bacterial resistance and showed topical in vivo efficacy.
• CBD was found to selectively kill a subset of Gram-negative bacteria, including Neisseria gonorrhoeae.
• Membrane disruption was identified as CBD's primary antimicrobial mechanism.

Conclusions:

• Cannabidiol possesses broad-spectrum antimicrobial properties with potential against challenging pathogens.
• CBD's mechanism of action and favorable resistance profile suggest its utility in combating antimicrobial resistance.
• CBD analogs represent a promising avenue for developing a novel class of antibiotics.